New hope for Tough-to-Treat lung cancer: major trial tests promising drug combo

This study is testing whether adding an experimental drug called AK112 to standard chemotherapy works better than chemotherapy alone for people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) whose previous targeted therapy has failed. About 322 participants will be randomly assigned to receive either the AK112 combination or a placebo with chemotherapy, followed by maintenance treatment for up to two years. The main goal is to see if the new combination can keep the cancer from growing for a longer period.